


Source: Company & KSI Research

Figure 3. Actual vs Projected Product Type 4M24



Source: Company & KSI Research

SMRA Marketing Sales Highlights

SMRA's Marketing Sales declined in 4M24 to IDR 283.94Bn / 6% (vs 4M23 461.50Bn / 9%) against SMRA's target of IDR 5Tn.

Marketing sales were contributed by Bekasi at IDR 87.21Bn / 20.3% of annual target of IDR 430Bn, Makassar at IDR 23.74Bn / 11.9% of annual target of IDR 200Bn, Serpong at IDR 95.49Bn / 7.6% of annual target of IDR 1.25Tn, Bandung amounting to IDR 34.9Bn / 5.8% of the annual target of IDR 600Bn, Crown Gading (Taruma Jaya) IDR 29.03Bn / 5.3% of the annual target of IDR 550Bn, and Kelapa Gading IDR 13.49Bn / 3.2% of the annual target of IDR 420Bn.

4M24 Marketing Sales by Product Type.

SMRA's product type contribution in 4M24, namely House became the largest contribution with growth of IDR 227.86Bn / 7.0% from annual target of IDR 3.17Tn (vs 4M23 IDR 106.47Bn / 3.8% from annual target of IDR 2.81Tn).

Landplots decreased to IDR 16.08Bn / 3.8% of annual target of IDR 420Bn (vs 4M23 IDR 39.15Bn / 4.9% of annual target of IDR 800Bn).

Apartments grew by IDR 26.53Bn / 3.6% from annual target of IDR 730Bn (vs 4M23 IDR 8.46Bn / 1.9% from annual target of IDR 450Bn).

Shoplots decreased to IDR 13.47Bn / 2.0% of the annual target of IDR 660Bn (vs 4M23 IDR 303.89Bn / 32.7% of the annual target of IDR 930Bn).


Comment

We see SMRA has the potential for performance recovery and growth in 2024, given its FY2023 results. SMRA is currently trading at IDR 510, has a fair value of IDR 600 with a P/E of 9.4x which is below 5Y AVG and has a PBV of 0.8x still below 5Y AVG.





APPENDIX



Source: Company & KSI Research

Figure 6. Actual Achieved vs Projection by Landplots





Figure 5. Actual Achieved vs Projection by Shoplots



Source: Company & KSI Research

Figure 7. Actual Achieved vs Projection by Apartments



Source: Company & KSI Research

Figure 8. Actual Achieved vs Projection by Office, Commercial







OTHER DISCLOSURES

All Kiwoom's research reports made available to clients are simultaneously available on our own website http://www.kiwoom.co.id/. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your sales representative. Any data discrepancies in this report could be the result of different calculations and/or adjustments.

DISCLAIMER This report has been prepared and issued by PT Kiwoom Sekuritas. Information has been obtained from sources believed to be reliable but PT Kiwoom Sekuritas do not warrant its completeness or accuracy. Forward-looking information or statements in this report contain information that is based on forecast of future results, estimates of amounts not yet determinable, assumptions, and therefore involve known and unknown risks and uncertainties which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

To the fullest extent allowed by law, PT Kiwoom Sekuritas shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred of suffered by any person or organization arising from reliance on or use of any information contained on this report. The information that we provide should not be construed in any manner whatsoever as, personalized advice.

No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. This report is being supplied to you solely for your information and may not be reproduced by, further distributed to or published

